BridgeBio?s Pipeline Expansion Continues as Portfolio?s Milestones Approach

BridgeBio Pharma Inc. is poised to achieve its goal of rapidly bringing treatments for genetic diseases and genetically defined cancers to the market with two different products expected to be submitted to the US Food and Drug Administration before the end of 2021 ? just four years after the company?s first big funding round. Palo […]

Click to view original post